Global Dermatology Focus Almirall is a global biopharmaceutical leader focused on medical dermatology with a diversified portfolio targeting atopic dermatitis, psoriasis, actinic keratosis and acne, supported by a worldwide footprint (100 plus countries, 15 affiliates) and integrated R&D and manufacturing capabilities. This structure creates opportunities for licensing, co development, or exclusive distribution partnerships across multiple geographies and indications.

AI Driven R&D The company is accelerating discovery and development through AI enabled collaborations, notably with Evotec and Absci, expanding dermatology targets and shortening timelines. This presents an opportunity for joint discovery deals, licensing of AI optimized candidates, or co investment in AI driven programs to de risk early stage assets in dermatology.

Evidence Based Growth Almirall showcases clinical and real world evidence across eczema, psoriasis, actinic keratosis and acne at major conferences such as the American Academy of Dermatology 2026, reinforcing payer and clinician value. This supports post marketing studies, payer evidence packages, and data driven market access strategies to expedite product adoption.

Manufacturing Strength With one research and development center and four production facilities, Almirall has regional manufacturing capabilities that can support contract development and toll manufacturing of dermatology products, with improved supply chain resilience and faster scale up for co developed assets.

Global Expansion Network A broad global footprint with operations in 100 plus countries via 15 affiliates and a strategic partnership network enables rapid market entry, co promotion, and distribution collaborations in new geographies, channels, or payer ecosystems.